Nxera Pharma, the Japan-based company with an R&D facility on Granta Park, has launched insomnia treatment QUVIVIQ ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

In a report released yesterday, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Centessa Pharmaceuticals (CNTA – Research ...

Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily developing its lead orexin agonist, ORX-750. ORX-750 targets narcolepsy ...

Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or ...

Spiromacrocyclic compounds acting as orexin OX2 receptor agonists have been described in an H. Lundbeck A/S patent and reported to be useful for the treatment of type 1 and type 2 narcolepsy.

its novel dual orexin receptor antagonist, for the treatment of adult patients in South Korea with insomnia. Insomnia, characterized by difficulties in sleep onset and/or sleep maintenance ...